TY - JOUR
T1 - Folate-targeted immunotherapies
T2 - Passive and active strategies for cancer
AU - Farran, Batoul
AU - Pavitra, Eluri
AU - Kasa, Prameswari
AU - Peela, Sujatha
AU - Rama Raju, Ganji Seeta
AU - Nagaraju, Ganji Purnachandra
N1 - Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/2
Y1 - 2019/2
N2 - The glycoprotein FRα is a membrane-attached transport protein that is shielded from the immune system in healthy cells. However, it is upregulated in various malignancies, involved in cancer development and is also immunogenic. Furthermore, FRα is a tumor-associated antigen endowed with unique properties, thus rendering it a suitable target for immunotherapeutic development in cancer. Various anti- FRα immunotherapeutic strategies are thus currently being developed and clinically assessed for the treatment of various solid tumors. These approaches include passive anti-FRα immunotherapies, such as monoclonal antibodies, or active immunotherapies, such as CART, folate haptens and vaccines. In this review, we will explore the advances in the field of FRα-based immune therapies and discuss both their successes and shortcomings in the clinical setting.
AB - The glycoprotein FRα is a membrane-attached transport protein that is shielded from the immune system in healthy cells. However, it is upregulated in various malignancies, involved in cancer development and is also immunogenic. Furthermore, FRα is a tumor-associated antigen endowed with unique properties, thus rendering it a suitable target for immunotherapeutic development in cancer. Various anti- FRα immunotherapeutic strategies are thus currently being developed and clinically assessed for the treatment of various solid tumors. These approaches include passive anti-FRα immunotherapies, such as monoclonal antibodies, or active immunotherapies, such as CART, folate haptens and vaccines. In this review, we will explore the advances in the field of FRα-based immune therapies and discuss both their successes and shortcomings in the clinical setting.
KW - Folate receptor
KW - Immune therapy
KW - Solid cancers
KW - Targeted therapy
KW - Vaccines
UR - http://www.scopus.com/inward/record.url?scp=85061339191&partnerID=8YFLogxK
U2 - 10.1016/j.cytogfr.2019.02.001
DO - 10.1016/j.cytogfr.2019.02.001
M3 - Review article
C2 - 30770191
AN - SCOPUS:85061339191
SN - 1359-6101
VL - 45
SP - 45
EP - 52
JO - Cytokine and Growth Factor Reviews
JF - Cytokine and Growth Factor Reviews
ER -
